Skip to content
Search

Latest Stories

New NHS ADHD Taskforce to partner with ICBs, PCS, Clinical Teams

New NHS ADHD Taskforce to partner with ICBs, PCS, Clinical Teams

Post-covid the NHS received an astounding 4.3 million page views related to ADHD

A new Attention-Deficit-Hyperactive disorder (ADHD) taskforce has been launched by National Health Services England (NHSE) to counter the challenges faced by many suffering from the neurodevelopmental condition.


The ADHD taskforce aligns with the NHS Long Term Plan's vision to revolutionise mental health services, with a specific emphasis on bolstering community-based care and reducing reliance on inpatient services.

The NHS has partnered with the government to tackle the escalating demands including increasing funding, improving system efficiency, altering the service provision model, and clinical prioritisation by bringing together expertise from across a broad range of sectors, including the NHS, education and justice, to help provide a joined-up approach in response to concerns around rising demand.

Over the past two decades, there has been a significant expansion in the acknowledgement and successful medical interventions for ADHD, leading to a steady rise in clinical requests throughout the UK.

However, the growing issue of prolonged waiting times for ADHD treatment has persisted without significant intervention, mainly due to the absence of defined targets for these wait times and the lack of regularly collected nationwide data.

This deficiency is primarily attributed to the absence of established targets for ADHD, unlike those in place for conditions like autism spectrum disorder.

Health leaders revealed that the taskforce's inception follows an exhaustive assessment of ADHD service provision and an analysis of the factors contributing to the surge in demand.

Initial findings highlighted overarching societal challenges such as capacity constraints, medication supply issues, service disparities, and inadequate data reliability, which the expert group will delve into further.

According to the National Institute for Health and Care Excellence (NICE), the prevalence of ADHD in adults is estimated at 3 per cent to 4 per cent, with a male-to-female ratio of approximately 3:1.

This compounds with the statistical data outcomes highlighted by NHSE.

According to it, ADHD emerged as the second most searched health condition on the NHS website in 2023, following Covid-19, with a staggering 4.3 million page views throughout the year.

The new initiative aims to engage with a spectrum of stakeholders, including patients, service providers, Integrated Care Boards (ICBs), primary care services, local authorities, schools, educational institutions, and clinical teams and compile insights that will be published by the end of the year.

This is in addition to NHSE's commitment to developing a national ADHD data improvement plan, conducting in-depth analyses of provider and commissioning landscapes, and showcasing innovative service delivery models from local health systems.

NHS chief executive Amanda Pritchard stressed the urgency of addressing the gaps in ADHD services, emphasising that "NHS staff across the country are working hard to ensure all patients requiring assessments and further support from ADHD services are seen as promptly as possible."

She underscored the complexity of the taskforce's mandate and emphasised the need for collaboration with partners and experts to drive tangible improvements.

Steve Russell, chief delivery officer at NHS England, highlighted ongoing efforts to enhance data collection and streamline pathways for ADHD patients, leveraging insights from the initial review.

More For You

US-UK pharmaceutical trade concerns as Liberal Democrat MPs urge protection from Trump tariffs.

UK prime minster Sir Keir Starmer with US president Donald Trump

Pic credit: Getty images

Pharma sector needs protecting from Trump tariffs, warn MPs

A group of Liberal Democrat MPs have written to health secretary Wes Streeting urging him to protect the pharmaceutical industry from US president Donald Trump’s trade war.

The five ministers from Oxfordshire, Olly Glover, Layla Moran, Calum Miller, Charlie Maynard, and Freddie van Mierlo, have warned that Trump’s campaign to raise tariffs has already led to “catastrophic damage”.

Keep ReadingShow less
Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less